Sökning: id:"swepub:oai:gup.ub.gu.se/66191" >
Relapse prevention ...
Relapse prevention in pediatric patients with ADHD treated with atomoxetine: a randomized, double-blind, placebo-controlled study.
-
Michelson, David (författare)
-
Buitelaar, Jan K (författare)
-
Danckaerts, Marina (författare)
-
visa fler...
-
- Gillberg, Christopher, 1950 (författare)
- Gothenburg University,Göteborgs universitet,Institutionen för kvinnors och barns hälsa, Avdelningen för barn- och ungdomspsykiatri,Institute for the Health of Women and Children, Dept of Child and Adolescent Psychiatry
-
Spencer, Thomas J (författare)
-
Zuddas, Alessandro (författare)
-
Faries, Douglas E (författare)
-
Zhang, Shuyu (författare)
-
Biederman, Joseph (författare)
-
visa färre...
-
(creator_code:org_t)
- 2004
- 2004
- Engelska.
-
Ingår i: Journal of the American Academy of Child and Adolescent Psychiatry. - 0890-8567. ; 43:7, s. 896-904
- Relaterad länk:
-
https://gup.ub.gu.se...
Abstract
Ämnesord
Stäng
- OBJECTIVE: Attention-deficit/hyperactivity disorder (ADHD) is typically treated over extended periods; however, few placebo-controlled, long-term studies of efficacy have been reported. METHOD: In a global multicenter study, children and adolescents who responded to an initial 12-week, open-label period of treatment with atomoxetine, a nonstimulant treatment for ADHD, were randomized to continued atomoxetine treatment or placebo for 9 months under double-blind conditions. RESULTS: A total of 416 patients completed acute atomoxetine treatment and were randomized. At end point, atomoxetine was superior to placebo in preventing relapse defined as a return to 90% of baseline symptom severity (proportion relapsing: atomoxetine 65 of 292 [22.3%], placebo 47 of 124 [37.9%], p =.002). The proportion of patients with a 50% worsening in symptoms post-randomization was also lower on atomoxetine (atomoxetine 83 of 292 [28.4%], placebo 59 of 124 [47.6%], p <.001). Compared with patients in the placebo group, atomoxetine-treated patients had superior psychosocial functioning at end point. Discontinuations for adverse events were low in both groups, and tolerability was similar to that observed in acute treatment trials. CONCLUSIONS: In patients who responded favorably to 12 weeks of initial treatment, atomoxetine was superior to placebo in maintaining response for the ensuing 9 months. This result supports the value of maintenance treatment with atomoxetine in patients with ADHD who respond to initial treatment.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Psykiatri (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Psychiatry (hsv//eng)
Nyckelord
- Attention Deficit Disorder with Hyperactivity
- drug therapy
- Child
- Double-Blind Method
- Female
- Humans
- Male
- Propylamines
- therapeutic use
- Recurrence
- prevention & control
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas